Your browser doesn't support javascript.
loading
Pattern, timing and predictors of recurrence after surgical resection of chromophobe renal cell carcinoma.
Neves, Joana B; Vanaclocha Saiz, Leyre; Abu-Ghanem, Yasmin; Marchetti, Marta; Tran-Dang, My-Anh; El-Sheikh, Soha; Barod, Ravi; Beisland, Christian; Capitanio, Umberto; Cullen, David; Klatte, Tobias; Ljungberg, Börje; Mumtaz, Faiz; Patki, Prasad; Stewart, Grant D; Dabestani, Saeed; Tran, Maxine G B; Bex, Axel.
Afiliação
  • Neves JB; Division of Surgery and Interventional Science, University College London, London, UK.
  • Vanaclocha Saiz L; Specialist Centre for Kidney Cancer, Royal Free London NHS Foundation Trust, Royal Free Hospital, Pond street, London, NW3 2QG, UK.
  • Abu-Ghanem Y; Faculty of Medical Sciences, University College London, London, UK.
  • Marchetti M; Specialist Centre for Kidney Cancer, Royal Free London NHS Foundation Trust, Royal Free Hospital, Pond street, London, NW3 2QG, UK.
  • Tran-Dang MA; Specialist Centre for Kidney Cancer, Royal Free London NHS Foundation Trust, Royal Free Hospital, Pond street, London, NW3 2QG, UK.
  • El-Sheikh S; Department of Pathology, Royal Free London NHS Foundation Trust, London, UK.
  • Barod R; Department of Pathology, Royal Free London NHS Foundation Trust, London, UK.
  • Beisland C; Specialist Centre for Kidney Cancer, Royal Free London NHS Foundation Trust, Royal Free Hospital, Pond street, London, NW3 2QG, UK.
  • Capitanio U; Department of Clinical Medicine, University of Bergen, Bergen, Norway.
  • Cullen D; Department of Urology, Haukeland University Hospital, Bergen, Norway.
  • Klatte T; Department of Urology and Division of Experimental Oncology, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy.
  • Ljungberg B; Specialist Centre for Kidney Cancer, Royal Free London NHS Foundation Trust, Royal Free Hospital, Pond street, London, NW3 2QG, UK.
  • Mumtaz F; Department of Urology, Royal Bournemouth Hospital, Bournemouth, UK.
  • Patki P; Department of Surgery, University of Cambridge, Cambridge, UK.
  • Stewart GD; Department of Surgical and Perioperative Sciences, Urology and Andrology, Umeå University, Umeå, Sweden.
  • Dabestani S; Specialist Centre for Kidney Cancer, Royal Free London NHS Foundation Trust, Royal Free Hospital, Pond street, London, NW3 2QG, UK.
  • Tran MGB; Specialist Centre for Kidney Cancer, Royal Free London NHS Foundation Trust, Royal Free Hospital, Pond street, London, NW3 2QG, UK.
  • Bex A; Department of Surgery, University of Cambridge, Cambridge, UK.
World J Urol ; 39(10): 3823-3831, 2021 Oct.
Article em En | MEDLINE | ID: mdl-33851271
ABSTRACT

PURPOSE:

Currently there are no specific guidelines for the post-operative follow-up of chromophobe renal cell carcinoma (chRCC). We aimed to evaluate the pattern, location and timing of recurrence after surgery for non-metastatic chRCC and establish predictors of recurrence and cancer-specific death.

METHODS:

Retrospective analysis of consecutive surgically treated non-metastatic chRCC cases from the Royal Free London NHS Foundation Trust (UK, 2015-2019) and the international collaborative database RECUR (15 institutes, 2006-2011). Kaplan-Meier curves were plotted. The association between variables of interest and outcomes were analysed using univariate and multivariate Cox proportional hazards regression models with shared frailty for data source.

RESULTS:

295 patients were identified. Median follow-up was 58 months. The five and ten-year recurrence-free survival rates were 94.3% and 89.2%. Seventeen patients (5.7%) developed recurrent disease, 13 (76.5%) with distant metastases. 54% of metastatic disease diagnoses involved a single organ, most commonly the bone. Early recurrence (< 24 months) was observed in 8 cases, all staged ≥ pT2b. 30 deaths occurred, of which 11 were attributed to chRCC. Sarcomatoid differentiation was rare (n = 4) but associated with recurrence and cancer-specific death on univariate analysis. On multivariate analysis, UICC/AJCC T-stage ≥ pT2b, presence of coagulative necrosis, and positive surgical margins were predictors of recurrence and cancer-specific death.

CONCLUSION:

Recurrence and death after surgically resected chRCC are rare. For completely excised lesions ≤ pT2a without coagulative necrosis or sarcomatoid features, prognosis is excellent. These patients should be reassured and follow-up intensity curtailed.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Carcinoma de Células Renais / Neoplasias Renais / Recidiva Local de Neoplasia Tipo de estudo: Etiology_studies / Guideline / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Carcinoma de Células Renais / Neoplasias Renais / Recidiva Local de Neoplasia Tipo de estudo: Etiology_studies / Guideline / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2021 Tipo de documento: Article